evipedia.ai
← Back

Therapeutic Plasma Exchange for Health & Longevity

Evidence Review created on 10/24/2026 using AI4L / Opus 5.5

Also known as: TPE, Plasma Exchange, PE, PLEX, PEX, Plasmapheresis, Plasma Dilution

Motivation

Therapeutic plasma exchange (plasmapheresis) is a procedure in which a machine draws blood, separates out the liquid plasma, discards it, and returns the blood cells together with a protein replacement solution. Removing a large share of the circulating plasma in a few hours dilutes whatever that plasma carries, including proteins and other substances whose levels rise with age. That idea has made a long-established hospital procedure a candidate for slowing aging.

For decades the procedure has been used to clear harmful antibodies in immune disorders. Interest in aging grew from animal experiments in which old and young mice shared blood, and from later work asking whether simply diluting old plasma, without any young blood, could have similar effects. Commercial longevity clinics now offer repeated sessions to healthy older adults, and the approach has also been tested in Alzheimer’s disease.

This review examines the human and animal evidence on plasma exchange for brain aging, measures of biological age, and the removal of environmental contaminants. It weighs that evidence against the procedure’s known risks and costs, and describes protocols, monitoring and open questions for health-focused adults considering it.

Benefits - Risks - Protocol - Conclusion

The following items give a high-level overview of therapeutic plasma exchange (TPE, removal of a person’s plasma and its replacement with a protein solution, usually albumin, the main blood protein) as an aging intervention.

Rhonda Patrick’s FoundMyFitness also has a members-only Q&A and two short research digests, on a mouse plasma-dilution study and on apheresis (machine blood filtering) lowering PFAS (persistent industrial “forever chemicals”). Chris Kresser’s site mentions plasmapheresis only briefly, in a guest’s remarks within a broad longevity episode, and Life Extension Magazine only within a broad conference summary; other candidates were systematic reviews, news coverage, or provider-authored work such as a 2021 editorial by apheresis physician Dobri Kiprov.

Grokipedia

Plasmapheresis

An AI-written encyclopedia entry on procedure mechanics, disease indications, plasma donation and complications, with a short passage on experimental plasma dilution research for aging.

Examine

No Examine article on therapeutic plasma exchange exists. Examine.com covers supplements and nutrition and does not typically cover medical procedures such as apheresis.

ConsumerLab

No ConsumerLab article on therapeutic plasma exchange exists. ConsumerLab tests consumer health products and does not typically cover medical procedures.

Systematic Reviews

No systematic review has assessed plasma exchange for healthy aging; the reviews below cover its closest tested benefits and its principal risks.

Mechanism of Action

An apheresis machine (a blood-cell separator) draws blood, spins off the plasma, and returns the cells with a replacement fluid, usually 5% albumin. Exchanging one plasma volume removes roughly 60% of circulating proteins, which refill from tissues and new synthesis over days to weeks. Citrate, added to stop clotting in the machine, binds calcium. As a procedure, TPE has no half-life or metabolism of its own.

Three explanations compete for any rejuvenating effect:

  • Dilution of age-elevated factors: The Conboy group proposes that old plasma carries excess signaling proteins, for example in the TGF-β (transforming growth factor beta, a scarring and inflammation pathway) and NF-κB (a master switch of inflammation) pathways, whose dilution resets tissue repair (Mehdipour et al., 2020, co-authored by apheresis physician Dobri Kiprov).
  • Removal of specific harmful molecules: Amyloid-β (the Alzheimer’s plaque protein) binds albumin in blood, so removing it may draw more out of the brain (Boada et al., 2020, sponsored by albumin maker Grifols).
  • Effects of what is infused: Fresh albumin and, in some protocols, intravenous immunoglobulin (IVIG) may drive the changes; immune-cell shifts appeared mainly with IVIG in a Buck Institute trial (Fuentealba et al., 2025; Kiprov co-founded the provider Circulate, and co-authors Verdin and Furman are members).

Against all three, removed complement proteins (immune-defense proteins) returned to baseline within about a month (Kim et al., 2022, procedures by Kiprov’s Global Apheresis), and repeated plasma removal without albumin replacement moved aging clocks the wrong way (Borsky et al., 2025).

Historical Context & Evolution

Plasmapheresis began in the early twentieth century as an animal-laboratory technique and became a clinical treatment once automated cell separators made large exchanges safe. Its original and main use is removing harmful substances (excess antibodies, abnormal proteins or toxins) in disorders such as Guillain–Barré syndrome (an autoimmune nerve paralysis), myasthenia gravis (antibody-driven muscle weakness) and certain blood and kidney diseases.

The longevity interest came from heterochronic parabiosis (surgically joining an old and a young animal so they share circulation), a method used for about a century (Conboy et al., 2013). In 2005, old mice joined to young partners regained muscle and liver regenerative capacity (Conboy et al., 2005), and in 2011 old blood was shown to impair brain cell renewal and memory in young mice (Villeda et al., 2011). These findings spawned commercial “young plasma” infusions, which the FDA (Food and Drug Administration) cautioned against in 2019 and again in 2024 (FDA, 2024).

In 2013 Kiprov proposed intermittent exchange of old plasma for young donor plasma to delay cellular senescence (cell aging) (Kiprov, 2013). In 2020 the Conboy laboratory reported that diluting old mouse plasma with saline and albumin matched the effects of young blood (Mehdipour et al., 2020), shifting the hypothesis from adding youthful factors to removing old ones. Human data followed: a Grifols-sponsored Alzheimer’s trial (Boada et al., 2020), biomarker studies (Kim et al., 2022), and conflicting 2025 trials reporting lower (Fuentealba et al., 2025) and higher (Borsky et al., 2025) aging-clock readings. Neither has settled the question.

Expected Benefits

High 🟩 🟩 🟩

Faster Recovery in Antibody-Mediated Disease ⭕️ Not Central to Health & Longevity

Clearing harmful antibodies is the procedure’s established use. In Guillain–Barré syndrome, a Cochrane review pooling six randomized trials from independent groups, including the North American Guillain-Barré Syndrome Study Group and the French Cooperative Group, found faster and more complete recovery than supportive care (Chevret et al., 2017). Walsh’s group pooled vasculitis trials and found a lower 12-month risk of kidney failure (Walsh et al., 2022). These benefits bear on acute autoimmune disease, not on aging in healthy adults; the healthy-aging data remain epigenetic (DNA-methylation) and protein biomarkers.

Magnitude: RR (relative risk) 1.64 (95% CI, confidence interval, the range likely to contain the true effect: 1.37 to 1.96) for improvement by at least one disability grade at four weeks versus supportive care in Guillain–Barré syndrome.

Medium 🟩 🟩

Slower Functional Decline in Mild-to-Moderate Alzheimer’s Disease ⚠️ Conflicted

In AMBAR, a sham-controlled (simulated-procedure) phase 2b/3 (mid-to-late-stage) trial of 347 patients sponsored by albumin and IVIG maker Grifols, exchanges slowed loss of daily function (Boada et al., 2020). Taragano’s Argentine group, with a device-maker co-author, reported slower decline versus historical controls (Taragano et al., 2025). AMBAR’s cognitive co-primary missed significance, mild-stage patients did not change, and a meta-analysis pooling plasma exchange with other blood products found no cognitive benefit (Fei et al., 2022). Net, one industry-funded trial supports slower decline in moderate disease.

Magnitude: 3.5 points less decline than sham on the ADCS-ADL (Alzheimer’s Disease Cooperative Study–Activities of Daily Living, a 0–78 function scale) at 14 months (95% CI 0.4 to 6.6); ADAS-Cog (a cognitive test scale) difference −2.1 points (95% CI −4.4 to 0.2, not significant).

Low 🟩

Transient Lowering of Cholesterol ⚠️ Conflicted

Exchange every two weeks in five patients with homozygous familial hypercholesterolemia (inherited extreme cholesterol) lowered peak cholesterol (Thompson et al., 1985); donor plasmapheresis lowered it (Borsky et al., 2025). A year-long donation trial found no lasting difference (Gasiorowski et al., 2022); both lack albumin exchange (indirect). Net, lowering appears transient.

Magnitude: Peak serum cholesterol 37% lower with exchange every two weeks (no control group).

Relief of Post-COVID-19 Condition ⚠️ Conflicted

A case report by apheresis provider Kiprov described symptom improvement after plasmapheresis in long COVID (Kiprov et al., 2021). A double-blind trial in 50 patients found six exchanges no better than sham on any efficacy measure (España-Cueto et al., 2025). Net, the controlled evidence shows no benefit.

Magnitude: Functional improvement (Post-COVID-19 Functional Status Scale grade 1–2) at 90 days in 24% with exchange versus 40% with sham; symptoms, quality of life and cognition did not differ between groups.

Speculative 🟨

Lower Epigenetic Age ⚠️ Conflicted

Epigenetic clocks fell versus sham, mostly with IVIG, then faded (Fuentealba et al., 2025); an albumin pilot lowered biomarker age (Gilmutdinova et al., 2022); albumin-free donation, indirect, raised them (Borsky et al., 2025). Net: unresolved.

Lower Circulating PFAS and Microplastic Levels

Plasma donation, indirect as it omits albumin exchange, lowered PFAS versus observation (Gasiorowski et al., 2022); an uncontrolled Circulate-run series lowered blood microplastics (Weinstein et al., 2026). Both are unvalidated biomarkers.

Younger Blood Protein and Immune Profile

Uncontrolled exchanges plus IVIG in eight people shifted proteins and immune markers toward young levels (Kim et al., 2022); AMBAR exchanges lowered inflammatory mediators (Gonzalo et al., 2024, Grifols authors). Clinical relevance is unknown.

Multi-Tissue Rejuvenation in Old Mice

In old mice, a single exchange of half the plasma for saline-albumin improved muscle repair, liver fibrosis (scarring), brain cell renewal and memory (Mehdipour et al., 2020; Mehdipour et al., 2021). The basis is animal-only.

Benefit-Modifying Factors

  • Genetic polymorphisms: No trial reports results by genotype. AMBAR’s arms differed in APOE4 carriers (a cholesterol-transport gene variant raising Alzheimer’s risk) (Boada et al., 2020); a Mayo Clinic pilot in APOE4 carriers enrolled three patients, with no published results (NCT03887741).
  • Baseline biomarkers: In the Buck trial, baseline glucose, calcium, monocytes (a white-cell type) and platelets predicted falling clocks (Fuentealba et al., 2025); in firefighters, PFAS fell most in the highest quarter of baseline levels (post hoc, an unplanned analysis) (Gasiorowski et al., 2022).
  • Sex: No trial reports sex-specific benefit. With donor plasmapheresis, calcium and blood-cell changes were more pronounced in women and hormone changes in men (Borsky et al., 2025), so response may differ by sex.
  • Pre-existing conditions: In AMBAR, moderate Alzheimer’s disease (MMSE, a 30-point cognitive screening test, 18–21) showed slower decline, while mild disease (MMSE 22–26) showed no change on the primary scales (Boada et al., 2020).
  • Age: In uncontrolled data, protein-noise markers fell more sharply in people aged 60 to over 70 than in those aged 46–52 (Kim et al., 2022); healthy-aging trial participants were mostly over 50, so younger adults lack data.

Potential Risks & Side Effects

High 🟥 🟥 🟥

No risk reaches High: the procedural-reaction excess rests on one sponsor-led trial program (AMBAR), the infection excess from several groups’ vasculitis trials comes from immunosuppressed patients and is contradicted by Guillain–Barré trials, and most other safety data are uncontrolled registries and case series.

Medium 🟥 🟥

Citrate binds calcium, causing tingling and cramps, while fluid shifts cause hypotension (low blood pressure), dizziness and presyncope (near-fainting). In sham-controlled AMBAR, with Grifols co-authors, these ranked among the commonest procedure-related events (Boada et al., 2023); a WAA (World Apheresis Association, whose members perform apheresis) registry analysis with device-maker co-authors lists tingling and hypotension as commonest (Haubner et al., 2025). A 50-patient sham-controlled trial found similar safety in both arms (España-Cueto et al., 2025). Net, the larger trial shows a clear excess of mostly mild reactions.

Magnitude: At least one procedure-related adverse event in 16.9% of full-volume exchanges versus 1.1% of sham procedures; most were mild and transient.

Vascular Access Complications

Large-bore central catheters can cause site infection, clotting, bleeding and vessel injury (Kaplan, 2012). In AMBAR, exchanges through central catheters had more adverse events than those through arm veins, mainly catheter-site redness, dizziness and fainting (Boada et al., 2023). Healthy adults with good arm veins can usually avoid central lines.

Magnitude: At least one adverse event in 20.1% of central-access versus 13.1% of peripheral-access exchanges in the active arms; sham procedures 1.4% and 0.9%.

More Serious Adverse Events When IVIG Is Added

Several longevity protocols add IVIG after each exchange. In AMBAR, the two arms receiving it had about twice the serious-adverse-event rate of the albumin-only and sham arms, and more dropouts (Boada et al., 2020). This applies to the add-on, not to albumin-only exchange.

Magnitude: Serious adverse events in 20.3–22.1% of patients in the IVIG arms versus 10.3% with albumin only and 10.1% with sham.

Low 🟥

Serious Infection from Antibody Depletion ⚠️ Conflicted

Albumin replacement removes antibodies; repeated sessions caused hypogammaglobulinemia (abnormally low antibody levels) (Volkin et al., 1982). Vasculitis trials, indirect because exchange was given with immunosuppressants (immune-suppressing drugs), found more serious infections (Walsh et al., 2022). Guillain–Barré trials found no excess (Chevret et al., 2017). Net, excess appears only with immunosuppression.

Magnitude: RR 1.27 (95% CI 1.08 to 1.49) for serious infection at 12 months versus no plasma exchange with immunosuppression in vasculitis, an absolute increase of 2.7% to 13.5% depending on baseline risk; RR 0.91 (95% CI 0.73 to 1.13) without it in Guillain–Barré syndrome.

Clotting Factor Depletion and Bleeding

With albumin replacement, clotting factors fell 23–55% per exchange and most recovered within 48 hours, but fibrinogen (the main clotting protein) stayed low with frequent sessions (Volkin et al., 1982). Hemorrhage was rare across 15,658 reported procedures (Mokrzycki & Kaplan, 1994).

Magnitude: Fibrinogen 51% below baseline after three exchanges in one week; hemorrhage in 0.02% of procedures (no control group).

Allergic and Anaphylactoid Reactions

Hives, flushing and, rarely, anaphylactoid (allergy-like shock) reactions come mainly from protein replacement fluids, far more often with donor plasma than albumin (Mokrzycki & Kaplan, 1994). The Buck trial’s corrected full text records one mild albumin reaction; its abstract cites two adverse events requiring discontinuation (Fuentealba et al., 2025).

Magnitude: Adverse reactions in 1.4% of albumin-replaced versus 20% of plasma-replaced treatments; one mild allergic reaction in 240 active procedures (0.42%) in the sham-controlled Buck trial, which reports no sham-arm rate.

When donor plasma replaces the removed plasma, as in young-donor protocols, antibodies in that plasma can cause transfusion-related acute lung injury (sudden lung inflammation with low blood oxygen). Case reports describe it during plasma-replaced exchange (Askari et al., 2002; P’ng et al., 2008). Albumin-only exchange avoids this risk.

Magnitude: Not quantified in available studies. Only case reports exist for plasma exchange, so no incidence or comparison-group rate has been measured.

Rare Severe Cardiopulmonary Events and Death ⚠️ Conflicted

Serious cardiovascular and respiratory events occurred in 0.2% of procedures (Mokrzycki & Kaplan, 1994), severe events 0.2 per 100 in the practitioner-run WAA registry (Stegmayr et al., 2025), and many deaths in severely ill patients (Kaplan, 2012). Guillain–Barré trials showed no excess (Chevret et al., 2017). Net, excess is small.

Magnitude: Death in 0.05% (8 of 15,658) of reported procedures; severe adverse events 0.20 per 100 procedures (no control group).

Mineral, Protein and Homocysteine Shifts with Frequent Plasma Removal

In healthy donors, repeated plasma removal without albumin replacement lowered calcium, phosphorus, total protein and albumin and raised homocysteine (an amino acid linked to vascular risk) (Borsky et al., 2025); this is indirect for albumin-replaced exchange. Twice-weekly donation may lower ferritin (stored iron) (D’aes et al., 2024).

Magnitude: Direction only: the declines and the homocysteine rise reached significance after eight sessions; the literature reports no between-group outcome figure.

Speculative 🟨

Acceleration of Epigenetic Aging Clocks

In an independent trial, each added plasma removal without albumin replacement raised GrimAge and DunedinPACE (mortality- and pace-of-aging clocks) estimates (Borsky et al., 2025). This may be a transient stress response.

Rebound of Removed Factors

Complement proteins returned to baseline within a month (Kim et al., 2022) and clock changes faded by later sessions (Fuentealba et al., 2025). Compensatory resynthesis is suspected; the basis is mechanistic.

Risk-Modifying Factors

  • Genetic polymorphisms: No genetic variant is known to change plasma exchange risk. Inherited bleeding disorders such as von Willebrand disease (an inherited shortage of a clotting protein) may add to clotting-factor depletion (theoretical).
  • Baseline biomarkers: Low starting IgG, fibrinogen, platelets or calcium leave less reserve; pre-session IgG stayed below range in AMBAR (Grifols et al., 2023, Grifols authors), and low-certainty evidence suggests twice-weekly donation may push IgG below 6 g/L (D’aes et al., 2024).
  • Sex: Calcium fell after repeated plasmapheresis in women but not in men (Borsky et al., 2025), suggesting more citrate and calcium effects in women; no study reports sex-specific rates of serious events.
  • Pre-existing conditions: Neurological diagnoses carried more hypotension in the practitioner-run WAA registry (Stegmayr et al., 2025); heart failure, symptomatic coronary disease, lung disease, active infection and active cancer excluded participants from the Buck trial (Fuentealba et al., 2025).
  • Age: In AMBAR’s older Alzheimer’s population, adverse-event rates matched those reported for other indications (Boada et al., 2023); frailty, poor veins and polypharmacy (taking many drugs) at the older end raise access and interaction risks.

Key Interactions & Contraindications

  • ACE inhibitors (angiotensin-converting enzyme inhibitors, blood pressure drugs; e.g., lisinopril, enalapril, ramipril): Avoid within 24 hours of a session. All 14 users had flushing, hypotension or breathing difficulty during albumin-replaced exchange versus 7% of others (Owen & Brecher, 1994). Mitigation: 24-hour hold.
  • Monoclonal antibodies (laboratory-made antibody drugs; e.g., rituximab, adalimumab, evolocumab): Caution. Exchange 24–72 hours after rituximab infusion removed 47–54% of the dose, lowering exposure (Puisset et al., 2013); others are mostly unstudied (Ibrahim et al., 2007; Cheng et al., 2017). Mitigation: dosing after sessions.
  • Anticoagulants and antiplatelets (anti-clotting drugs; e.g., warfarin, apixaban, clopidogrel): Monitor. One case found only 10% apixaban removal (Pilková et al., 2024); another linked a session to stroke from suspected apixaban removal (Holt et al., 2024); clotting-factor depletion may raise bleeding (theoretical). Mitigation: coagulation checks.
  • Antihypertensives and diuretics (blood pressure and fluid-removing drugs; e.g., amlodipine, losartan, hydrochlorothiazide): Caution (theoretical). Additive blood pressure drop during fluid shifts, a common procedure reaction (Boada et al., 2023); consequence is fainting. Mitigation used in practice: taking the morning dose after the session.
  • IVIG and other infused biologics (protein-based drugs; e.g., antithymocyte globulin, clotting-factor concentrates): Monitor (theoretical). Products given before an exchange are removed with the plasma, losing effect; the Kim protocol infuses IVIG right after sessions (Kim et al., 2022). Mitigation: infusing them after sessions.
  • NSAIDs (nonsteroidal anti-inflammatory drugs; e.g., ibuprofen, naproxen) and aspirin: Caution (theoretical). Platelet inhibition adds to clotting-factor depletion after exchange, raising bruising and access-site bleeding. Mitigation: pausing them on session days.
  • Calcium-containing antacids (e.g., calcium carbonate): Beneficial interaction. Calcium prophylaxis cut hypocalcemic (low-calcium) symptoms from 9.1% to 1% of treatments (Mokrzycki & Kaplan, 1994). Mitigation: calcium before or during sessions.
  • Fish oil, vitamin E, ginkgo, high-dose curcumin: Caution (theoretical). Additive antiplatelet effects on top of depleted fibrinogen may increase access-site bleeding. Mitigation: pausing them for 2–3 days around sessions.
  • Blood pressure-lowering supplements (e.g., beetroot nitrate, magnesium, garlic extract): Caution (theoretical). Additive effect with the hypotension that exchanges commonly cause (Boada et al., 2023); consequence is fainting. Mitigation: omitting them on session mornings.
  • Protein-bound or lipid-carried supplements (e.g., vitamin D, CoQ10 (coenzyme Q10), vitamin E): Monitor (theoretical). Carrier proteins and lipoproteins (cholesterol-carrying particles) are removed with plasma, so blood levels may fall transiently and reduce supplement effect. Mitigation: taking them after sessions and testing levels.
  • Vaccinations: Caution (theoretical). Exchange removes at least a third of circulating IgG per session (Volkin et al., 1982), so antibodies from a recent vaccine are partly removed, reducing protection. Mitigation: vaccinating at least 2 weeks after a session.
  • Blood or plasma donation: Avoid combining (theoretical for the combination). Frequent plasma removal can lower IgG below 6 g/L and ferritin (D’aes et al., 2024); adding exchange compounds antibody and protein depletion. Mitigation: no donation during exchange courses.
  • Immunosuppressants and rapamycin (e.g., prednisone, sirolimus, everolimus): Caution. Exchange combined with immunosuppression raised serious infections (Walsh et al., 2022); rapamycin in this setting is unstudied (theoretical). Mitigation: IgG monitoring and spacing sessions.

Populations who should avoid Therapeutic Plasma Exchange:

Risk Mitigation Strategies

Parameters below follow common practice unless cited.

  • Calcium prophylaxis: Calcium given with exchange cut citrate-related tingling and cramps from 9.1% to 1% of treatments (Mokrzycki & Kaplan, 1994); a practitioner-run WAA registry reanalysis found no harm from prophylactic calcium (Toss et al., 2018). Mitigates citrate hypocalcemia.
  • Arm veins over central catheters: Peripheral access had fewer procedure adverse events (13.1% vs 20.1%) in AMBAR (Boada et al., 2023). Mitigates catheter infection, clotting and site reactions.
  • Albumin rather than donor plasma: Albumin replacement had far fewer reactions than fresh frozen plasma (1.4% vs 20%) (Mokrzycki & Kaplan, 1994). Mitigates allergic and anaphylactoid reactions and donor-plasma lung injury.
  • Pausing ACE inhibitors: Withholding them for at least 24 hours before each session (Owen & Brecher, 1994) prevents flushing, severe hypotension and breathing difficulty.
  • Pre-session IgG and fibrinogen checks: Sessions are postponed if IgG is below 6 g/L (D’aes et al., 2024) or fibrinogen below about 1.0 g/L, the usual plasma-supplementation trigger (Wodajo et al., 2024). Mitigates infection and bleeding from cumulative depletion.
  • Spacing sessions: Three exchanges in one week produced hypogammaglobulinemia and halved fibrinogen (Volkin et al., 1982); longevity protocols use monthly or paired-monthly sessions (Fuentealba et al., 2025). Mitigates cumulative antibody and protein loss.
  • Hydration, a meal and reclining: Drinking about 500 mL of fluid and eating before the session, and reclining during it, reduce vasovagal (reflex) fainting. Mitigates procedure-related hypotension.
  • Medication timing: Antibody drugs, IVIG and other plasma-retained medications are given after rather than before a session (Cheng et al., 2017). Prevents loss of drug effect.
  • Albumin-only unless IVIG is specifically intended: IVIG arms had about twice the serious adverse events in AMBAR (Boada et al., 2020). Mitigates IVIG-related serious adverse events.
  • Emergency-capable setting: Severe events occur at about 0.2 per 100 procedures in the practitioner-run WAA registry (Stegmayr et al., 2025); resuscitation equipment and apheresis-trained staff mitigate harm from rare anaphylactoid or cardiopulmonary events.
  • B vitamins with frequent sessions: Folate, vitamin B6 and vitamin B12 were proposed to offset the homocysteine rise seen with repeated plasma removal (Borsky et al., 2025). Mitigates homocysteine elevation.

Therapeutic Protocol

Doses below are cited to their source; timing, cycling and titration steps without a citation reflect common practice.

  • Buck–Circulate healthy-aging regimen: One plasma volume replaced with 5% albumin, monthly for six sessions or two sessions in one week monthly for three months, optionally with 2 g IVIG (Fuentealba et al., 2025); popularized by Kiprov and Circulate.
  • Conboy–Kiprov dilution regimen: One plasma volume exchanged for 5% albumin, followed by 2 g of 10% IVIG, repeated in roughly monthly rounds (Kim et al., 2022); developed by Irina and Michael Conboy at UC Berkeley with Kiprov.
  • AMBAR Alzheimer’s regimen: Six weekly full exchanges (about 2.4–2.7 L), then twelve monthly low-volume exchanges (about 0.7–0.9 L) with 20–40 g albumin, with or without 10–20 g IVIG (Boada et al., 2023); developed by Grifols and Mercè Boada.
  • Donation-style plasmapheresis: Plasma removed without albumin replacement every 2 weeks (Borsky et al., 2025) or every 6 weeks (Gasiorowski et al., 2022); a distinct, lower-volume alternative tested for PFAS reduction.
  • Time of day: No study compared session timing. AMBAR exchanges lasted about 100–110 minutes (Boada et al., 2023); daytime outpatient sessions after a light meal are typical.
  • Recovery kinetics (half-life equivalent): Most clotting factors recover within 48 hours, fibrinogen more slowly (Volkin et al., 1982); complement proteins return to baseline within about a month (Kim et al., 2022), setting the minimum useful interval.
  • Single versus paired sessions: Monthly single sessions lowered clock estimates by 1.32 years, more than paired sessions within one week (Fuentealba et al., 2025), suggesting more frequent sessions are not necessarily better.
  • Genetic polymorphisms: No genotype-guided protocol exists; AMBAR did not report results by APOE4 status (Boada et al., 2020).
  • Sex: Exchange volume is calculated from height, weight and hematocrit (Boada et al., 2023), so smaller people, often women, exchange less plasma; calcium declines with repeated plasma removal were seen in women (Borsky et al., 2025).
  • Age: Trials enrolled adults over 50 (Buck; Fuentealba et al., 2025) and older Alzheimer’s patients (AMBAR; Boada et al., 2020); no data exist for adults under 40, and frail older adults are usually given peripheral access and lower volumes.
  • Baseline biomarkers: Baseline routine labs predicted clock responders in the Buck trial (Fuentealba et al., 2025); baseline IgG, fibrinogen and calcium set how often sessions can be repeated.
  • Pre-existing conditions: Moderate, not mild, Alzheimer’s disease showed slower decline in AMBAR (Boada et al., 2020); cardiac and lung disease were Buck trial exclusions (Fuentealba et al., 2025).
  • Anticoagulation and calcium: Exchanges use citrate anticoagulant, and calcium prophylaxis reduces citrate symptoms (Mokrzycki & Kaplan, 1994).

Discontinuation & Cycling

  • Intended duration: Longevity protocols are six-session courses over three to six months (Fuentealba et al., 2025) and AMBAR ran 14 months (Boada et al., 2020); no protocol is designed as lifelong, and long-term repeat schedules are untested.
  • Withdrawal effects: No withdrawal syndrome is known; removed proteins re-accumulate, with complement back to baseline within about a month (Kim et al., 2022).
  • Tapering: No taper is needed. AMBAR’s step-down from weekly full exchanges to monthly low-volume exchanges is a maintenance design, not a withdrawal measure (Boada et al., 2023).
  • Cycling: Clock effects seen after early sessions were absent at later sampling (Fuentealba et al., 2025), so intermittent courses with recovery gaps, rather than continuous frequent sessions, are common practice.
  • Stopping add-ons: When IVIG is part of the regimen it is stopped together with the exchanges; any IVIG effect may outlast them (theoretical).

Sourcing and Quality

  • Replacement fluid: 5% human albumin is a pharmaceutical plasma-derived product from manufacturers such as Grifols, CSL Behring, Octapharma and Takeda; it causes far fewer reactions than donor plasma (Mokrzycki & Kaplan, 1994).
  • Immunoglobulin products: IVIG used in longevity protocols is a pooled, plasma-derived antibody product, for example Octagam 10% (Kim et al., 2022); it adds cost and risk, and its aging use rests only on the small trials above.
  • Equipment: Centrifugal separators such as Terumo BCT’s Spectra Optia were used in the human longevity studies (Fuentealba et al., 2025); registry data for this device, reported with manufacturer co-authors, show low plasma exchange adverse-event rates (Haubner et al., 2025).
  • Operator and setting: Hospital apheresis units follow ASFA (American Society for Apheresis) guidance (Connelly-Smith et al., 2023); ASFA’s members earn income from performing apheresis. Longevity clinics vary in staffing and emergency capability.
  • What to look for: Physician oversight, apheresis-trained nurses, pre-session labs (IgG, fibrinogen, calcium, blood count), a calcium protocol, peripheral access, resuscitation equipment, and disclosed financial ties behind any provider-run research.
  • Provider conflicts: Much healthy-aging data come from parties selling the procedure: Circulate, co-founded by Buck Institute CEO and trial co-author Eric Verdin (GeekWire, 2025) and by Kiprov (Fuentealba et al., 2025), and Kiprov’s Global Apheresis (Kim et al., 2022).

Practical Considerations

  • Time to effect: Biomarker shifts appeared after about three sessions (one to three months) and faded later (Fuentealba et al., 2025); functional differences in Alzheimer’s disease emerged over 14 months (Boada et al., 2020).
  • Common pitfalls: Treating clock changes as proof of health benefit; attributing IVIG add-on effects to plasma exchange; accepting central catheters when arm veins suffice; forgetting to pause ACE inhibitors; scheduling vaccines or antibody drugs just before sessions.
  • Regulatory status: Plasma exchange is established for disease indications graded by ASFA, whose members perform apheresis (Connelly-Smith et al., 2023); healthy aging is not among them. The FDA states that “young plasma” infusions marketed for aging have no demonstrated benefit (FDA, 2024).
  • Cost and accessibility: Commercial longevity sessions cost about $8,000–10,000 each and are not insured (GeekWire, 2025). Because insurers have no incentive to fund aging uses, independent trial funding is scarce, leaving most evidence to providers and plasma-product makers.

Interaction with Foundational Habits

  • Sleep: None known directly. No study measured sleep; post-session fatigue and fluid shifts could briefly disturb it (theoretical). Practical: sessions are usually scheduled earlier in the day.
  • Nutrition: Indirect, supportive. Adequate protein supports albumin and antibody resynthesis between sessions (theoretical); calcium before sessions offsets citrate binding (Mokrzycki & Kaplan, 1994); folate, B6 and B12 were proposed against the homocysteine rise seen with frequent plasma removal (Borsky et al., 2025).
  • Exercise: Not studied; possibly blunting on session days. Fluid shifts and hypotension during exchange (Boada et al., 2023) mean hard training on the same day may raise fainting risk (theoretical); light activity on other days is unaffected.
  • Stress management: Possible indirect interaction. The independent donor trial attributed rising clock readings to a possible procedure-related stress response (Borsky et al., 2025); cortisol was not measured. Relaxation during the two-hour session is common practice.

Monitoring Protocol & Defining Success

Baseline testing before a first session establishes reserves and screens for contraindications: blood count, IgG, fibrinogen and clotting tests, ionized calcium, total protein and albumin, kidney and liver panels, and, if biological-age effects are being tracked, an epigenetic clock and any specific target such as PFAS (Fuentealba et al., 2025; Grifols et al., 2023).

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Immunoglobulin G (IgG) About 7–16 g/L (standard reference range) Safety check: low IgG raises infection risk and delays sessions Pre-session sample; postpone below 6 g/L (D’aes et al., 2024); low pre-session IgG persisted in AMBAR (Grifols et al., 2023)
Fibrinogen About 2–4 g/L (standard reference range) Safety check: low levels raise bleeding risk and delay sessions Recovers more slowly than other clotting factors (Volkin et al., 1982); pair with PT and aPTT (prothrombin time and activated partial thromboplastin time, clotting-time tests)
Ionized calcium About 1.15–1.30 mmol/L (standard reference range) Safety check: low values predict citrate reactions Pre-session, and during sessions if tingling occurs; calcium fell with repeated plasma removal (Borsky et al., 2025)
Complete blood count (platelets, hemoglobin) Platelets about 150–400 ×10⁹/L (standard reference range) Safety check: low platelets add to bleeding risk Platelets and hemoglobin dip after exchange (Grifols et al., 2023); pre-session sample
Albumin and total protein Albumin about 35–50 g/L (standard reference range) Safety check: falls signal inadequate replacement or recovery Fell with plasma removal without albumin replacement (Borsky et al., 2025); pre-session sample
Homocysteine About 5–15 µmol/L (standard reference range) Safety check: rose with frequent plasma removal Fasting sample; rose after eight sessions (Borsky et al., 2025); pair with folate and vitamin B12
Epigenetic clock (e.g., GrimAge, DunedinPACE) No established target; track change from own baseline Marker the intervention is expected to change Same lab and clock each time, same time of day; fell in the Buck trial and rose in the Czech trial (Fuentealba et al., 2025; Borsky et al., 2025)
PFAS panel (e.g., PFOS) No established target; track change from own baseline Marker the intervention is expected to change PFOS (perfluorooctane sulfonate, the main PFAS measured); relevant with high exposure; fell with plasma donation (Gasiorowski et al., 2022)

Ongoing monitoring follows the session cadence: IgG, fibrinogen, calcium and blood count before every session (for example monthly), clotting tests if anticoagulants are used, epigenetic clocks at baseline, after the third session and 3–6 months after the course ends, and PFAS or homocysteine every 3–6 months during repeated courses. Pre-session values matter more than post-session values, because proteins dip transiently after every exchange. Success is defined by stable safety labs alongside the outcome being targeted, not by a single clock reading.

Qualitative markers:

  • Energy levels and post-session fatigue
  • Lightheadedness, tingling or cramps during sessions
  • Bruising or bleeding at access sites
  • Frequency of infections between courses
  • Cognitive clarity and ease of daily tasks

Emerging Research

  • Frailty trial (not yet recruiting): NCT07836127 will give 34 pre-frail or frail Chinese adults monthly albumin exchanges, randomized to IVIG or none, with no non-exchange control; primary endpoint is frailty-score change one month post-treatment (primary completion May 2028). A positive result would add a functional aging signal; a null result would weaken functional claims.
  • Young-donor plasma exchange in mild cognitive impairment: Oslo’s ADDITION-MCI pilot (NCT06234436) replaced 16–26 L of plasma with young-donor plasma in 12 patients; procedures were feasible and adverse events matched known plasma exchange risks (Søraas et al., 2026). Registered completion (December 2025) has passed; registry status unknown.
  • Open-label frailty study: A 100-participant US study scoring the Clinical Frailty Scale (NCT05054894) had a registered completion of May 2025; its status is unknown and no results are posted.
  • Albumin versus no-albumin plasmapheresis: A Russian randomized trial in 80 adults aged 40–55 (NCT04897113) passed registered completion (December 2022), status unknown, no results posted; the center’s 20-person pilot reported normalized aging biomarkers with albumin and lower biological age at 30 days (Gilmutdinova et al., 2022), unlike the Czech no-albumin trial (Borsky et al., 2025).
  • Published biomarker trials: The Buck sham-controlled trial (NCT06534450; registry status unknown, estimated completion August 2025) and the completed Czech donor trial (NCT05004220) have published results (Fuentealba et al., 2025; Borsky et al., 2025), reported under Expected Benefits and Potential Risks; they point in opposite directions.
  • Microplastic and PFAS removal: A Circulate-run series reported lower blood microplastics after exchange (Weinstein et al., 2026); a 20-person study of double-filtration plasmapheresis (a filter-based variant; NCT07658443), had a registered completion of September 2026, is still listed as enrolling by invitation, and has no results posted. Neither links reduction to health outcomes.
  • Future research areas: An IVIG-only arm to separate the add-on, clinical endpoints such as frailty or cognition, and longer follow-up are missing. A 2026 compilation of human studies on next-generation clocks classed plasmapheresis among interventions that accelerated epigenetic aging (Johnson & Sinclair, 2026).

Conclusion

Plasma exchange removes much of a person’s plasma and replaces it with a protein solution, on the idea that diluting substances that build up with age lets the body reset. Its appeal for health-focused adults is one repeatable procedure that might act on many aging processes at once.

The evidence is thin and conflicting. In people with moderate Alzheimer’s disease, one large trial suggested slower loss of daily function, but its memory measure fell short, people with mild disease showed no change, and the trial was paid for by a company that sells the replacement protein. In healthy older adults, small studies report younger-looking blood markers and biological-age test results, yet an independent study found those tests moving the other way, and the most promising readings faded with repeated sessions and were strongest when donor antibodies were added. Removal of some long-lasting industrial chemicals is plausible from blood-donation studies; animal results are striking but unconfirmed in people.

The risks are better understood: brief drops in blood pressure, tingling, problems with large intravenous lines, temporary loss of antibodies and clotting proteins, and a higher infection risk in patients already on immune-suppressing drugs; serious events are rare in experienced settings. Much of the healthy-aging research comes from clinics and companies selling the procedure or its supplies, and sessions are expensive and uninsured. Plasma exchange remains an experimental longevity tool whose benefits in healthy people are unproven and whose short-term risks are modest but real.

Top - Benefits - Risks - Protocol